Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer.
PET-CT
cancer
ketogenic diet
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
19 May 2020
19 May 2020
Historique:
received:
22
04
2020
revised:
09
05
2020
accepted:
15
05
2020
entrez:
23
5
2020
pubmed:
23
5
2020
medline:
11
2
2021
Statut:
epublish
Résumé
A ketogenic diet is expected to be an effective support therapy for patients with cancer, but the degree and duration of carbohydrate restriction are unclear. We performed a case series study of a new ketogenic diet regimen in patients with different types of stage IV cancer. Carbohydrates were restricted to 10 g/day during week one, 20 g/day from week two for three months, and 30 g/day thereafter. A total of 55 patients participated in the study, and data from 37 patients administered the ketogenic diet for three months were analyzed. No severe adverse events associated with the diet were observed. Total ketone bodies increased significantly, and both fasting blood sugar and insulin levels were suppressed significantly for three months after completion of the study. Five patients showed a partial response on Positron emission tomography-computed tomography (PET-CT) at three months. Three and seven patients showed complete and partial responses, respectively at one year. Median survival was 32.2 (maximum: 80.1) months, and the three-year survival rate was 44.5%. After three months on the ketogenic diet, the serum Alb, BS, and CRP (ABC) score could be used to stratify the patients into groups with significantly different survival rates (
Identifiants
pubmed: 32438645
pii: nu12051473
doi: 10.3390/nu12051473
pmc: PMC7284721
pii:
doi:
Substances chimiques
Blood Glucose
0
Insulin
0
Ketone Bodies
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
This study was partly performed under a joint research between the University of Osaka, Meiji Co., Ltd., and Nissin Oillio. Hagihara holds the position of Joint Research Chair in collaboration with Meiji Co., Ltd. who produced the ketogenic formula, and Nisshin Oillio produced the MCT oil. Kajimoto is a member of the Joint Research group. Other authors have no competing interests.
Références
Annu Rev Nutr. 2017 Aug 21;37:51-76
pubmed: 28826372
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
Br J Cancer. 2003 Sep 15;89(6):1028-30
pubmed: 12966420
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Ann Oncol. 2016 Mar;27(3):502-8
pubmed: 26681680
Crit Rev Oncol Hematol. 2017 Apr;112:41-58
pubmed: 28325264
Nutr Metab (Lond). 2010 Sep 10;7:74
pubmed: 20831808
Clin Nutr. 2017 Oct;36(5):1187-1196
pubmed: 28689670
N Engl J Med. 2018 Nov 22;379(21):2052-2062
pubmed: 30462943
Aging (Albany NY). 2019 Feb 27;11(4):1283-1304
pubmed: 30811347
Nutr Metab (Lond). 2010 Apr 22;7:33
pubmed: 20412570
Clin Nutr. 2019 Oct;38(5):1986-1994
pubmed: 30473444
Front Nutr. 2018 Mar 29;5:20
pubmed: 29651419
Br J Cancer. 2010 Mar 16;102(6):966-71
pubmed: 20160725
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Brain Dev. 2016 Aug;38(7):628-37
pubmed: 26923720
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Front Nutr. 2020 Mar 11;7:21
pubmed: 32219096
Clin Nutr ESPEN. 2016 Apr;12:e1-e6
pubmed: 28531663
Nutr Metab (Lond). 2015 Mar 11;12:12
pubmed: 25798181
Oncologia. 1956;9(2):75-83
pubmed: 13335077
Mol Metab. 2020 Mar;33:102-121
pubmed: 31399389
Eur J Cancer. 1998 Mar;34(4):503-9
pubmed: 9713300
Gastroenterology. 2007 Nov;133(5):1423-9
pubmed: 17904132
Nutr Metab (Lond). 2011 Jul 27;8(1):54
pubmed: 21794124
Cell Metab. 2017 Sep 5;26(3):547-557.e8
pubmed: 28877458
Ther Adv Med Oncol. 2019 Aug 20;11:1758835919866964
pubmed: 31467597
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
N Engl J Med. 2011 Sep 8;365(10):919-26
pubmed: 21899452
CA Cancer J Clin. 2010 Jul-Aug;60(4):207-21
pubmed: 20554718